ReviewThe AAPS journal2019

Systemic Bioequivalence Is Unlikely to Equal Target Site Bioequivalence for Nanotechnology Oncologic Products.

Jessie L-S Au et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.